For the quarter ended March 2026, Amgen (AMGN Quick QuoteAMGN - Free Report) reported revenue of $8.62 billion, up 5.8% over the same period last year. EPS came in at $5.15, compared to $4.90 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $8.47 billion, representing a surprise of +1.71%. The company delivered an EPS surprise of +8.87%, with the consensus EPS estimate being $4.73.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Repatha- ROW: $411 million compared to the $373.03 million average estimate based on six analysts. The reported number represents a change of +31.3% year over year.
• Product Sales- BLINCYTO- ROW: $194 million versus $118.06 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +100% change.
• Product Sales- Nplate- U.S.: $283 million versus $215.63 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +40.8% change.
• Product Sales- XGEVA- U.S.: $228 million versus the six-analyst average estimate of $238.6 million. The reported number represents a year-over-year change of -36.7%.
• Product Sales- BLINCYTO- Total: $415 million compared to the $410.16 million average estimate based on seven analysts. The reported number represents a change of +12.2% year over year.
• Product Sales- KYPROLIS- Total: $330 million compared to the $328.67 million average estimate based on seven analysts. The reported number represents a change of +1.9% year over year.
• Product Sales- Repatha- Total: $876 million versus the seven-analyst average estimate of $819.8 million. The reported number represents a year-over-year change of +33.5%.
• Product Sales- XGEVA- Total: $411 million versus $389.57 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -27.4% change.
• Product Sales- Prolia- Total: $727 million versus the seven-analyst average estimate of $831.86 million. The reported number represents a year-over-year change of -33.9%.
• Product Sales- Nplate- Total: $412 million versus the seven-analyst average estimate of $339.63 million. The reported number represents a year-over-year change of +31.6%.
• Product Sales- Vectibix- Total: $287 million compared to the $289.31 million average estimate based on seven analysts. The reported number represents a change of +7.5% year over year.
• Product Sales- Enbrel- Total: $320 million versus the seven-analyst average estimate of $426.94 million. The reported number represents a year-over-year change of -37.3%.

View all Key Company Metrics for Amgen here>>>

Shares of Amgen have returned -4.3% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.